Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Bioorg Khim ; 28(4): 308-14, 2002.
Artigo em Russo | MEDLINE | ID: mdl-12197387

RESUMO

A chemical modification of single-chain urokinase-type plasminogen activator (scu-PA) with phenylglyoxal under mild conditions resulted in the scu-PA derivatives with various numbers of the modified Arg residues. The study of properties of the resulting derivatives demonstrated that the modification of 4-12 Arg residues did not cause any loss of the activator, fibrinolytic, and potential amidase activities of the activator. The scu-PA with four modified Arg residues was found to be the most stable derivative in human blood plasma; it causes a more efficient lysis of plasma clots than the native activator. Three of four modified Arg residues are supposed to be within the 178RRHRGGS184 cluster, which was localized in the superficial loop of the scu-PA globule and was shown to interact with the complementary series of negatively charged residues in the molecule of the main plasma inhibitor PAI-1. The neutralization of positively charged Arg residues in this cluster decreases the affinity of scu-PA and the double chain urokinase-type plasminogen activator for PAI-1, which results in an enhancement of the stability in plasma and the fibrinolytic efficiency of the activator. The English version of the paper: Russian Journal of Bioorganic Chemistry, 2002, vol. 28, no. 4; see also http://www.maik.ru.


Assuntos
Fenilglioxal/química , Ativador de Plasminogênio Tipo Uroquinase/química , Arginina/química , Estabilidade de Medicamentos , Fibrinólise/efeitos dos fármacos , Humanos , Concentração de Íons de Hidrogênio , Indicadores e Reagentes , Ativador de Plasminogênio Tipo Uroquinase/sangue , Ativador de Plasminogênio Tipo Uroquinase/farmacologia
2.
Farmakol Toksikol ; 54(2): 46-50, 1991.
Artigo em Russo | MEDLINE | ID: mdl-1884796

RESUMO

In the experiments on guinea-pigs with venous thrombosis there were studied the fibrin- and thrombolytic effects of streptokinase, the plasmin-streptokinase complex and the acylated derivatives of the complex with various rates of reactivation. It was established that the acylated derivatives of the plasmin-streptokinase complex possess greater stability in the blood flow and lead to more prolonged stimulation of fibrinolysis at less magnitude of its systemic activation. Due to this the acylated derivatives of the plasmin-streptokinase complex produce less pronounced fibrinogenolysis. In connection with a high affinity to fibrin their thrombolytic action does not depend on the systemic activation of fibrinolysis.


Assuntos
Anistreplase/farmacologia , Fibrinólise/efeitos dos fármacos , Ativadores de Plasminogênio/farmacologia , Estreptoquinase/farmacologia , Animais , Anistreplase/síntese química , Anistreplase/uso terapêutico , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Cobaias , Ativadores de Plasminogênio/síntese química , Ativadores de Plasminogênio/uso terapêutico , Estreptoquinase/síntese química , Estreptoquinase/uso terapêutico , Trombose/sangue , Trombose/tratamento farmacológico , Trombose/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA